TREE NEWS reports: Bayer reported third-quarter adjusted EBITDA of €1.62 billion, beating the €1.42 billion market estimate, on sales of €10.05 billion versus €9.89 billion expected. The German group guided full-year adjusted EBITDA to €9.8 billion–€10.3 billion, against a €9.82 billion consensus, and projected negative free cash flow of €500 million–€1.5 billion, compared with an expected negative €1.61 billion.
Bayer Q3 adjusted EBITDA €1.62B beats €1.42B estimate; sales €10.05B
AI take
The headline beat matters less than the mix: Bayer's full-year EBITDA range straddles consensus rather than lifting it, suggesting the quarterly outperformance is not being extrapolated. The more telling line is free cash flow guidance, where the projected outflow is narrower than feared — a signal that cash discipline, not earnings growth, is carrying the story. For RWA and tokenization watchers, Bayer is a reminder that large-cap pharma cash-flow trajectories shape the collateral and credit narratives around real-world assets. Whether the improved cash outlook holds through year-end is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
3m ago
Chinese Regulator Opens Probe Into Pinming Technology Controller Mo Xujun for Market Manipulation
6m ago
Jiangxi Issues 5-Year Land Reserve Special Local Bond at 1.34%
12m ago
Hong Kong Q3 GDP rises 5.2% year on year
24m ago
US stocks shed $1.5T in October as AI selloff deepens
29m ago
HKEX to Launch 12 Stock Futures Contracts on Jan 18, 2027
32m ago
Guotai Haitong Wins 10B Yuan in PBOC’s Third SFISF Operation at 10bp